Tezepelumab Deemed Breakthrough But Can Phase III Reproduce Data?
Executive Summary
Biologic's breakthrough designation is based on Phase IIb PATHWAY data that showed tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma.